This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...
Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of ...
Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of its Allo Chassistm?ready-to-use, immune-cloaked iPSC cell lines derived ...
GlobalData on MSN1d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
20hon MSN
Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...
Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...
Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...
Cells are constantly on the move, whether in a developing embryo or metastatic cancer. But how do cells adapt to the new ...
Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, ...
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback